The researchers aimed to develop a novel transdermal delivery system for the anti-psychotic drug
A recent study undertaken at the University of Petra in Jordan has described the formation of room temperature therapeutic deep eutectic solvent (THEDES) of RIS, an antipsychotic drug that is used in the treatment of schizophrenia, mixed and manic states associated with bipolar disorder and irritability in children and adolescents with autism.
RIS is commercially available as a conventional tablet, disintegrating tablet, oral liquid solution and long-acting intramuscular injection. It’s thought creating a transdermal drug delivery system (TDDS) for RIS may help improve its typically low bioavailability. The conversion of the API into liquid form using deep eutectic solvents to form THEDES has reportedly been shown to have many formulation advantages, the company says, including enhanced skin permeation for transdermal drug delivery.
In this study, aimed at enhancing the skin permeability of RIS using eutectic systems, the researchers were reportedly able to achieve the formation of room temperature THEDES of RIS and some fatty acids using a simple method for preparation, potentially opening up opportunities for formulation innovation for this important pharmaceutical drug.
Freeze drying microscopy (FDM) can be used to determine the crystallisation, collapse and eutectic temperatures of pharmaceutical solutions intended to freeze dry. In this study, FDM was successfully used to follow the eutectic phase changes for the THEDES of RIS. These changes were captured using a Linkam FDCS196 varying temperature control stage.
Faisal T. Al-Akayleh, Associate Professor at the University of Petra said: “Eutectic systems’ phase changes are temperature-dependant, which we were able to control and monitor with the Linkam FDCS196 stage. The stage provided valuable information regarding the phase change and transitions the drug undergoes as a function of temperature, clarifying the interpretation of the differential thermal analysis results.”
Duncan Stacey, Sales and Marketing Director, Linkam Scientific Instruments said: “We are pleased that the FDCS196 stage played an important role in the development of a novel liquid pharmaceutical formulation of RIS to overcome problems of poor drug solubility, dissolution and permeation. Hopefully, this work will lead to new formulations of RIS that will benefit patients around the world. The FDCS196 is used in a wide range of research, from increasing the shelf life of drugs and vaccines, to food processing and preservation.”